Published in Proc Natl Acad Sci U S A on October 10, 2013
Cell of origin for malignant gliomas and its implication in therapeutic development. Cold Spring Harb Perspect Biol (2015) 0.85
Ras-mediated modulation of pyruvate dehydrogenase activity regulates mitochondrial reserve capacity and contributes to glioblastoma tumorigenesis. Neuro Oncol (2015) 0.83
Contemporary murine models in preclinical astrocytoma drug development. Neuro Oncol (2014) 0.81
A preclinical orthotopic model for glioblastoma recapitulates key features of human tumors and demonstrates sensitivity to a combination of MEK and PI3K pathway inhibitors. Dis Model Mech (2014) 0.80
Core pathway mutations induce de-differentiation of murine astrocytes into glioblastoma stem cells that are sensitive to radiation but resistant to temozolomide. Neuro Oncol (2016) 0.80
Modeling astrocytoma pathogenesis in vitro and in vivo using cortical astrocytes or neural stem cells from conditional, genetically engineered mice. J Vis Exp (2014) 0.79
Unlocking the promise of oncolytic virotherapy in glioma: combination with chemotherapy to enhance efficacy. Ther Deliv (2015) 0.78
Intrinsic astrocyte heterogeneity influences tumor growth in glioma mouse models. Brain Pathol (2016) 0.76
In vivo models of brain tumors: roles of genetically engineered mouse models in understanding tumor biology and use in preclinical studies. Cell Mol Life Sci (2014) 0.76
SNP Formation Bias in the Murine Genome Provides Evidence for Parallel Evolution. Genome Biol Evol (2015) 0.76
Genomic dynamics associated with malignant transformation in IDH1 mutated gliomas. Oncotarget (2015) 0.75
Finding degrees of separation: experimental approaches for astroglial and oligodendroglial cell isolation and genetic targeting. J Neurosci Methods (2014) 0.75
Perillyl alcohol: Dynamic interactions with the lipid bilayer and implications for long-term inhalational chemotherapy for gliomas. Surg Neurol Int (2016) 0.75
Genomic profiles of low-grade murine gliomas evolve during progression to glioblastoma. Neuro Oncol (2017) 0.75
Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature (2008) 75.40
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol (2007) 49.11
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09
IDH1 and IDH2 mutations in gliomas. N Engl J Med (2009) 32.41
Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell (2006) 21.66
Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev (2007) 17.20
Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev (2001) 15.97
Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat (2007) 12.98
The transcriptional network for mesenchymal transformation of brain tumours. Nature (2009) 8.44
Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell (2004) 8.16
Targeted disruption of the three Rb-related genes leads to loss of G(1) control and immortalization. Genes Dev (2000) 5.80
Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat Genet (2000) 5.28
p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature (2008) 5.00
T cell-specific loss of Pten leads to defects in central and peripheral tolerance. Immunity (2001) 4.62
The Gaggle: an open-source software system for integrating bioinformatics software and data sources. BMC Bioinformatics (2006) 4.05
Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev (2010) 3.99
Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta (2002) 3.77
Ablation of the retinoblastoma gene family deregulates G(1) control causing immortalization and increased cell turnover under growth-restricting conditions. Genes Dev (2000) 3.74
Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice. Nature (2001) 3.57
The INK4A/ARF locus and its two gene products. Curr Opin Genet Dev (1999) 3.50
PTEN gene mutations are seen in high-grade but not in low-grade gliomas. Cancer Res (1997) 3.15
Development of a novel mouse glioma model using lentiviral vectors. Nat Med (2009) 3.08
IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res (2009) 2.95
Cooperativity within and among Pten, p53, and Rb pathways induces high-grade astrocytoma in adult brain. Cancer Cell (2011) 2.87
p107 is a suppressor of retinoblastoma development in pRb-deficient mice. Genes Dev (1998) 2.53
Inactivation of pRB-related proteins p130 and p107 mediated by the J domain of simian virus 40 large T antigen. Mol Cell Biol (1997) 2.01
Proliferation of human malignant astrocytomas is dependent on Ras activation. Oncogene (1997) 1.95
Combinations of genetic mutations in the adult neural stem cell compartment determine brain tumour phenotypes. EMBO J (2009) 1.66
Characterization of astrocyte-specific conditional knockouts. Genesis (2007) 1.57
Astrocyte inactivation of the pRb pathway predisposes mice to malignant astrocytoma development that is accelerated by PTEN mutation. Cancer Cell (2002) 1.48
Genetic modeling of gliomas in mice: new tools to tackle old problems. Glia (2011) 1.28
Somatic induction of Pten loss in a preclinical astrocytoma model reveals major roles in disease progression and avenues for target discovery and validation. Cancer Res (2005) 1.24
Gene expression profiling of gliomas: merging genomic and histopathological classification for personalised therapy. Br J Cancer (2010) 1.24
Correlation of MR perfusion imaging and vessel tortuosity parameters in assessment of intracranial neoplasms. Technol Cancer Res Treat (2004) 1.13
High-grade glioma mouse models and their applicability for preclinical testing. Cancer Treat Rev (2009) 1.12
Genomic profiles of glioma. Curr Neurol Neurosci Rep (2011) 1.05
Mesenchymal high-grade glioma is maintained by the ID-RAP1 axis. J Clin Invest (2012) 0.98
Colocalization of glial fibrillary acidic protein, metallothionein, and MHC II in human, rat, NOD/SCID, and nude mouse skin keratinocytes and fibroblasts. J Invest Dermatol (2006) 0.90
Gliomagenesis arising from Pten- and Ink4a/Arf-deficient neural progenitor cells is mediated by the p53-Fbxw7/Cdc4 pathway, which controls c-Myc. Cancer Res (2012) 0.87
The brain and thymus have much in common: a functional analysis of their microenvironments. Immunol Today (2000) 0.77
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 71.08
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09
Patterns of somatic mutation in human cancer genomes. Nature (2007) 38.41
A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol (2005) 27.17
Integration of biological networks and gene expression data using Cytoscape. Nat Protoc (2007) 27.10
Whole-genome shotgun assembly and analysis of the genome of Fugu rubripes. Science (2002) 20.59
Analysis of genetic inheritance in a family quartet by whole-genome sequencing. Science (2010) 18.45
Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev (2007) 17.20
Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol (2008) 15.90
Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature (2002) 15.36
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell (2007) 12.52
Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol (2007) 10.49
A genomic regulatory network for development. Science (2002) 9.67
The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol (2002) 8.62
Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature (2004) 8.35
Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res (2003) 8.06
Pten dose dictates cancer progression in the prostate. PLoS Biol (2003) 7.62
A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res (2006) 6.91
Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell (2011) 6.43
Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med (2010) 6.38
The program of androgen-responsive genes in neoplastic prostate epithelium. Proc Natl Acad Sci U S A (2002) 5.98
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Lamin A/C deficiency causes defective nuclear mechanics and mechanotransduction. J Clin Invest (2004) 5.68
The Inferelator: an algorithm for learning parsimonious regulatory networks from systems-biology data sets de novo. Genome Biol (2006) 5.22
Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell (2002) 5.11
Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin Cancer Res (2007) 4.99
Coordinate regulation of energy transduction modules in Halobacterium sp. analyzed by a global systems approach. Proc Natl Acad Sci U S A (2002) 4.96
Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities. Cancer Res (2006) 4.80
Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells. Sci Transl Med (2013) 4.74
Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell (2011) 4.54
Olig2-regulated lineage-restricted pathway controls replication competence in neural stem cells and malignant glioma. Neuron (2007) 4.47
Integrated barcode chips for rapid, multiplexed analysis of proteins in microliter quantities of blood. Nat Biotechnol (2008) 4.40
Initialization, noise, singularities, and scale in height ridge traversal for tubular object centerline extraction. IEEE Trans Med Imaging (2002) 4.19
AID is required for the chromosomal breaks in c-myc that lead to c-myc/IgH translocations. Cell (2008) 4.13
PTEN-deficient intestinal stem cells initiate intestinal polyposis. Nat Genet (2007) 4.09
Role of genomic instability and p53 in AID-induced c-myc-Igh translocations. Nature (2006) 3.90
AID is required for c-myc/IgH chromosome translocations in vivo. Cell (2004) 3.89
Complementary profiling of gene expression at the transcriptome and proteome levels in Saccharomyces cerevisiae. Mol Cell Proteomics (2002) 3.89
Systems medicine: the future of medical genomics and healthcare. Genome Med (2009) 3.85
The microRNA miR-29 controls innate and adaptive immune responses to intracellular bacterial infection by targeting interferon-γ. Nat Immunol (2011) 3.77
Hippocampal short- and long-term plasticity are not modulated by astrocyte Ca2+ signaling. Science (2010) 3.77
Comparative epidemiology of human infections with avian influenza A H7N9 and H5N1 viruses in China: a population-based study of laboratory-confirmed cases. Lancet (2013) 3.77
Genetic alterations of phosphoinositide 3-kinase subunit genes in human glioblastomas. Brain Pathol (2004) 3.74
Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis. Cell (2005) 3.68
Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol (2011) 3.66
A multigene predictor of outcome in glioblastoma. Neuro Oncol (2009) 3.57
H2AX is required for recombination between immunoglobulin switch regions but not for intra-switch region recombination or somatic hypermutation. J Exp Med (2003) 3.55
Systems biology, proteomics, and the future of health care: toward predictive, preventative, and personalized medicine. J Proteome Res (2004) 3.46
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol (2010) 3.43
Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins. Nat Biotechnol (2004) 3.36
A predictive model for transcriptional control of physiology in a free living cell. Cell (2007) 3.35
T1DBase: integration and presentation of complex data for type 1 diabetes research. Nucleic Acids Res (2006) 3.25
Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet (2013) 3.19
Selective stimulation of astrocyte calcium in situ does not affect neuronal excitatory synaptic activity. Neuron (2007) 3.15
Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol (2008) 3.08
Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc Natl Acad Sci U S A (2008) 2.99
A data integration methodology for systems biology. Proc Natl Acad Sci U S A (2005) 2.93
Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discov (2013) 2.93
A molecular correlate to the Gleason grading system for prostate adenocarcinoma. Proc Natl Acad Sci U S A (2006) 2.89
Quantitative phosphoproteome analysis using a dendrimer conjugation chemistry and tandem mass spectrometry. Nat Methods (2005) 2.87
Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates. Nature (2009) 2.81
ATM prevents the persistence and propagation of chromosome breaks in lymphocytes. Cell (2007) 2.78
Dysregulated gene expression networks in human acute myelogenous leukemia stem cells. Proc Natl Acad Sci U S A (2009) 2.76
Genome sequence of Haloarcula marismortui: a halophilic archaeon from the Dead Sea. Genome Res (2004) 2.75
Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy. Nat Biotechnol (2008) 2.75
Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc Natl Acad Sci U S A (2006) 2.72
Diagnostic utility of major basic protein, eotaxin-3, and leukotriene enzyme staining in eosinophilic esophagitis. Am J Gastroenterol (2012) 2.70
What is the role of astrocyte calcium in neurophysiology? Neuron (2008) 2.70
The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas. J Neuropathol Exp Neurol (2004) 2.66
Abnormal nuclear shape and impaired mechanotransduction in emerin-deficient cells. J Cell Biol (2005) 2.66
A brain tumor segmentation framework based on outlier detection. Med Image Anal (2004) 2.62
Nesprin 4 is an outer nuclear membrane protein that can induce kinesin-mediated cell polarization. Proc Natl Acad Sci U S A (2009) 2.59
A progeroid syndrome in mice is caused by defects in A-type lamins. Nature (2003) 2.57
Extracellular microRNA: a new source of biomarkers. Mutat Res (2011) 2.55
Analysis of the human neurexin genes: alternative splicing and the generation of protein diversity. Genomics (2002) 2.54
Conditional knock-out of Kir4.1 leads to glial membrane depolarization, inhibition of potassium and glutamate uptake, and enhanced short-term synaptic potentiation. J Neurosci (2007) 2.44
Automatic brain tumor segmentation by subject specific modification of atlas priors. Acad Radiol (2003) 2.44
Influence of unrecognized molecular heterogeneity on randomized clinical trials. J Clin Oncol (2002) 2.39
Highly accurate two-gene classifier for differentiating gastrointestinal stromal tumors and leiomyosarcomas. Proc Natl Acad Sci U S A (2007) 2.38
Whole-slide imaging digital pathology as a platform for teleconsultation: a pilot study using paired subspecialist correlations. Arch Pathol Lab Med (2009) 2.30
Engineering GPCR signaling pathways with RASSLs. Nat Methods (2008) 2.29
Mechanisms promoting translocations in editing and switching peripheral B cells. Nature (2009) 2.27
Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers. J Pathol (2011) 2.27
A provisional regulatory gene network for specification of endomesoderm in the sea urchin embryo. Dev Biol (2002) 2.26
Regulatory gene networks and the properties of the developmental process. Proc Natl Acad Sci U S A (2003) 2.24
Multi-modal image set registration and atlas formation. Med Image Anal (2006) 2.23
NF-kappaB p50 and p52 regulate receptor activator of NF-kappaB ligand (RANKL) and tumor necrosis factor-induced osteoclast precursor differentiation by activating c-Fos and NFATc1. J Biol Chem (2007) 2.22
Her-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer. J Clin Oncol (2003) 2.20
Association between the various mutations in viral core promoter region to different stages of hepatitis B, ranging of asymptomatic carrier state to hepatocellular carcinoma. Am J Gastroenterol (2010) 2.20
Homozygous defects in LMNA, encoding lamin A/C nuclear-envelope proteins, cause autosomal recessive axonal neuropathy in human (Charcot-Marie-Tooth disorder type 2) and mouse. Am J Hum Genet (2002) 2.20
Engineering and selection of shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles. Mol Ther (2008) 2.19
Lung squamous cell carcinoma mRNA expression subtypes are reproducible, clinically important, and correspond to normal cell types. Clin Cancer Res (2010) 2.15
Loss of IP3 receptor-dependent Ca2+ increases in hippocampal astrocytes does not affect baseline CA1 pyramidal neuron synaptic activity. J Neurosci (2008) 2.14
An animal model of MYC-driven medulloblastoma. Cancer Cell (2012) 2.12
Hematopoietic stem cells contribute to the regeneration of renal tubules after renal ischemia-reperfusion injury in mice. J Am Soc Nephrol (2003) 2.12
MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. Clin Cancer Res (2009) 2.11
Hippocampal astrocytes in situ exhibit calcium oscillations that occur independent of neuronal activity. J Neurophysiol (2002) 2.09
Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology. J Neuropathol Exp Neurol (2003) 2.08
BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications. PLoS One (2011) 2.04